Bromuconazole

Synonyms: 糠菌唑
Bromuconazole 是一种具有口服有效性和血脑屏障通透性的三唑类杀菌剂,可保护作物免受各类真菌 (fungal) 污染,对多种癌细胞具有细胞毒性,能诱导癌细胞 G0/G1 期细胞周期阻滞并抑制 DNA 合成,诱导细胞骨架结构紊乱、遗传毒性损伤、凋亡 (apoptosis) 性细胞死亡及线粒体膜去极化,同时激活 caspase-3,诱导 ROS、p53 和 Bax 过量生成、脂质过氧化、SOD 和 CAT 活性升高,并下调 Bcl-2,还通过上调 p-ERK1/2 和 p-JNK 扰乱 MAPK 信号通路,抑制人滋养层细胞与子宫内膜细胞的细胞应激反应从而损害着床过程,可用于胶质瘤、结肠癌、生殖损伤 (着床功能障碍) 和心脏功能障碍的相关研究。
产品编号: MS-E16929 CAS No.: 116255-48-2 分子式: C13H12BrCl2N3O 分子量: 377.06
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Bromuconazole 是一种具有口服有效性和血脑屏障通透性的三唑类杀菌剂,可保护作物免受各类真菌 (fungal) 污染,对多种癌细胞具有细胞毒性,能诱导癌细胞 G0/G1 期细胞周期阻滞并抑制 DNA 合成,诱导细胞骨架结构紊乱、遗传毒性损伤、凋亡 (apoptosis) 性细胞死亡及线粒体膜去极化,同时激活 caspase-3,诱导 ROS、p53 和 Bax 过量生成、脂质过氧化、SOD 和 CAT 活性升高,并下调 Bcl-2,还通过上调 p-ERK1/2 和 p-JNK 扰乱 MAPK 信号通路,抑制人滋养层细胞与子宫内膜细胞的细胞应激反应从而损害着床过程,可用于胶质瘤、结肠癌、生殖损伤 (着床功能障碍) 和心脏功能障碍的相关研究。

生物实验数据

生物活性 Bromuconazole is an orally active, blood-brain barrier-permeable triazole fungicide that protects crops from various fungal contamination and exhibits cytotoxicity against multiple cancer cells by inducing G0/G1 cell cycle arrest and inhibiting DNA synthesis, inducing cytoskeletal disruption, genotoxic damage, apoptotic cell death, and mitochondrial membrane depolarization, activating caspase-3, inducing excessive production of ROS, p53, and Bax, lipid peroxidation, increased SOD and CAT activities, and downregulating Bcl-2, as well as disrupting the MAPK signaling pathway by upregulating p-ERK1/2 and p-JNK to suppress the cellular stress response in human trophoblast cells and endometrial cells and impair the implantation process, and can be used for research on glioma, colon cancer, reproductive injury (implantation dysfunction), and cardiac dysfunction.
体外研究
(In Vitro)

Bromuconazole (0-500 μM; 24 h) 可 F98、HCT116 细胞中诱导浓度依赖性细胞毒性,IC50 分别为 60、180 μM。
Bromuconazole (0-180 μM; 6-24 h) 可 F98、HCT116 细胞中诱导 G0/G1 期细胞周期阻滞并抑制 DNA 合成,诱导细胞骨架结构紊乱、遗传毒性损伤 (DNA 片段化和细胞核固缩)、凋亡性细胞死亡、线粒体膜去极化。
Bromuconazole (15-60 μM; 24 h) 可在大鼠胶质瘤 F98 细胞中诱导 p53 和 Bax mRNA 呈浓度依赖性上调、Bcl-2 mRNA 下调,并使 Bax/Bcl-2 比值升高,诱导 caspase-3 呈浓度依赖性激活。
Bromuconazole (45-180 μM; 24 h) 诱导 HCT116 细胞中 caspase-3 的浓度依赖性激活、ROS 过量生成、脂质过氧化、SOD 和 CAT 的活性升高。
Bromuconazole (0-50 mg/L; 48 h) 会损伤 HTR-8/SVneo 和 T HESCs 的细胞活力,暴露 48 h 后其 LC50 值分别为 28.05 mg/L 和 33.41 mg/L。
Bromuconazole (30 mg/L; 24-48 h) 可破坏 HTR-8/SVneo 和 T HESCs 的 3D 球体形成与自组装,通过调控凋亡相关基因表达异常并升高 BAX/BCL-XL 蛋白比值,诱导细胞发生凋亡,通过下调细胞周期相关基因的表达,诱导 G2/M 期细胞周期阻滞,通过降低线粒体膜电位、下调线粒体功能相关基因的表达,破坏线粒体功能。
Bromuconazole (30 mg/L; 30 min to 24 h) 可通过下调 SOD1 并上调内质网应激相关因子,在 HTR-8/SVneo 和 THESCs 细胞中诱导活性氧 (ROS) 积累与内质网 (ER) 应激。
Bromuconazole (30 mg/L; 15 min) 会通过上调 HTR-8/SVneo、T HESCs 细胞中的 p-ERK1/2 和 p-JNK,来扰乱 MAPK 信号通路。
Bromuconazole (30 mg/L; 24 h) 可通过失调促炎和抗炎细胞因子 mRNA 的表达,在 HTR-8/SVneo 和 THESCs 细胞中诱导炎症反应。
Bromuconazole (30 mg/L; 24-48 h) 可抑制 HTR-8/SVneo 和 T HESCs 的迁移。
Bromuconazole (10-250 μM; 24 h) 可诱导大鼠 H9C2 心肌细胞产生细胞毒性、破坏能量代谢、失调离子平衡及肌球蛋白合成相关基因的表达,并上调 LEF1 蛋白表达。

Cell Viability Assay

Cell Line: rat glioma F98 cells
Concentration: 0, 10, 20, 40, 60, 80, 100, 120, 140, 150 μM
Incubation Time: 24 h
Result: Caused concentration-dependent F98 cell death, with an IC50 of 60 μM after 24 h of treatment.

Cell Cycle Analysis

Cell Line: rat glioma F98 cells
Concentration: 15, 30, and
60 μM
Incubation Time: 24 h
Result: Caused dose-dependent accumulation of F98 cells in the G0/G1 phase: at 60 μM, G0/G1 phase cell distribution increased from 64.78% (untreated) to 89%.
Corresponding dose-dependent reduction in S phase cell distribution was observed: at 60 μM, S phase cell distribution decreased from 17.52% (untreated) to 1.5%.

Apoptosis Analysis

Cell Line: rat glioma F98 cells
Concentration: 15, 30, and
60 μM
Incubation Time: 24 h
Result: Induced concentration-dependent apoptosis: apoptosis levels were 23.61% at 15 μM, 33.86% at 30 μM, and 55.94% at 60 μM, compared to 1.55% in untreated cells.

Real Time qPCR

Cell Line: rat glioma F98 cells
Concentration: 15, 30, and
60 μM
Incubation Time: 24 h
Result: Caused concentration-dependent increases in p53 and Bax mRNA expression, and concentration-dependent decreases in Bcl-2 mRNA expression.
At 60 μM, p53 mRNA levels increased to 2.49-fold, Bax mRNA levels increased to 2.3-fold, Bcl-2 mRNA levels decreased to 0.3-fold, and the Bax/Bcl-2 ratio increased to 7.67-fold.

Cell Cytotoxicity Assay

Cell Line: human colon carcinoma HCT116 cells
Concentration: 0, 50, 100, 150, 200, 250, 300, 350, 400 μM
Incubation Time: 24 h
Result: Caused a concentration-dependent increase in HCT116 cell mortality, with an IC50 of 180 μM.

Cell Cycle Analysis

Cell Line: human colon carcinoma HCT116 cells
Concentration: 45, 90 and 180 μM
Incubation Time: 24 h
Result: Caused a concentration-dependent accumulation of cells in the G0/G1 phase (from 59.89% in untreated cells to 67.84%, 71.02%, and 84% at 45, 90, and 180 μM, respectively).
Caused a concentration-dependent reduction in cells in the S phase (from 18.9% in untreated cells to 11.03%, 9.26%, and 5.65% at 45, 90, and 180 μM, respectively).

Apoptosis Analysis

Cell Line: human colon carcinoma HCT116 cells
Concentration: 45, 90 and 180 μM
Incubation Time: 24 h
Result: Caused a concentration-dependent increase in apoptosis ratio (from 11.15% in untreated cells to 22.45%, 30.92%, and 39.75% at 45, 90, and 180 μM, respectively).
Induced light green staining and crescent-shaped nuclei in treated cells, consistent with apoptotic morphology.\nCaused a concentration-dependent increase in total apoptosis (early + late apoptosis) from 12.29% in untreated cells to 24.5%, 34.02%, and 43.85% at 45, 90, and 180 μM, respectively.

Cell Viability Assay

Cell Line: HTR-8/SVneo, T HESCs
Concentration: 0, 5, 10, 15, 20, 30, 40, and 50 mg/L
Incubation Time: 48 h
Result: Reduced cell viability in both cell lines.
Reached an LC50 value of 28.05 mg/L for HTR-8/SVneo cells.
Reached an LC50 value of 33.41 mg/L for T HESCs.

Apoptosis Analysis

Cell Line: HTR-8/SVneo, T HESCs
Concentration: 0, 10, 20,
30 mg/L (annexin V/PI staining); 30 mg/L (mRNA and protein analysis)
Incubation Time: 48 h (annexin V/PI staining); 24 h (mRNA and protein analysis)
Result: Increased HTR-8/SVneo early apoptotic cells by 171.58% and late apoptotic cells by 146.96%.
Upregulated HTR-8/SVneo mRNA expression of BAK and CASP1.
Downregulated HTR-8/SVneo mRNA expression of BCL2 and BCL2L1.
Increased the HTR-8/SVneo BAX/BCL-XL protein ratio by 208.17%.
Increased T HESCs early apoptotic cells by 171.58% and late apoptotic cells by 176.12%.
Upregulated T HESCs mRNA expression of BAX and CASP1.
Downregulated T HESCs mRNA expression of BCL2.
Increased the T HESCs BAX/BCL-XL protein ratio by 152.46%.

Cell Cycle Analysis

Cell Line: HTR-8/SVneo, T HESCs
Concentration: 0, 10, 20, and
30 mg/L (cell cycle analysis); 30 mg/L (mRNA analysis)
Incubation Time: 48 h (cell cycle analysis); 24 h (mRNA analysis)
Result: Reduced HTR-8/SVneo G0/G1 phase cells to 66.01%.
Increased HTR-8/SVneo S phase cells to 139.83%.
Increased HTR-8/SVneo G2/M phase cells to 118.42%.
Increased HTR-8/SVneo sub G1 phase cells to 234.14%.
Downregulated HTR-8/SVneo mRNA expression of CCNA2, CCNB1, CCND1, CCNE2, CDK1, and CDK4.
Reduced T HESCs G0/G1 phase cells to 85.95%.
Increased T HESCs G2/M phase cells to 138.99%.
Increased T HESCs sub G1 phase cells to 269.69%.
Downregulated T HESCs mRNA expression of CCNA2, CCNB1, CCND1, CCNE2, and CDK1 (no significant change in CDK4).

Real Time qPCR

Cell Line: HTR-8/SVneo, T HESCs
Concentration: 30 mg/L
Incubation Time: 24 h
Result: Upregulated HTR-8/SVneo mRNA expression of proinflammatory cytokines IL21, IL21R, and CXCR2.
Downregulated HTR-8/SVneo mRNA expression of anti-inflammatory cytokines IL4R and CCL2.
Upregulated T HESCs mRNA expression of proinflammatory cytokines IL1β, IL18R1, and CXCR2.
Downregulated T HESCs mRNA expression of anti-inflammatory cytokines IL4R and CCL2.

Cell Migration Assay

Cell Line: HTR-8/SVneo, T HESCs
Concentration: 30 mg/L
Incubation Time: 3-48 h (wound healing assay); 24 h (transwell assay)
Result: Delayed HTR-8/SVneo wound healing, with 15.78% of initial wound area remaining at 48 h (vs.
1.43% in control).
Reduced HTR-8/SVneo transwell-migrated cells to 52.50%.
Delayed T HESCs wound healing, with 7.61% of initial wound area remaining at 48 h (vs.
1.84% in control).
体内研究
(In Vivo)

Bromuconazole (13.8-32.8 mg/kg/天;口服;每日;90 天;84-200 mg/kg/天;局部给药;每日;90 天) 可在雄性白化大鼠中诱导剂量依赖性肝毒性,且口服途径的毒性强于局部给药;其特征包括肝酶水平升高、肝脏氧化应激、肝脏重量增加、组织病理学上的坏死性病变、肝脏 PXR 与 CYP3A1 表达及 CYP3A1 活性上调,以及肝脏 CAR 与 CYP2B1 表达下调。
Bromuconazole (50 ng/L-7.5 mg/L;i.g.;每日一次;连续 7 天 ) 暴露会通过扰乱心脏能量代谢、改变离子平衡与肌球蛋白合成基因表达,以及异常激活 LEF1,导致成年雄性 AB 品系斑马鱼产生心脏毒性。

Animal Model: albino rats (male, adult, 160-200 g)
Dosage: 13.8 mg/kg/day (oral); 32.8 mg/kg/day (oral); 84 mg/kg/day (topical); 200 mg/kg/day (topical)
Administration: p.o.; daily; 90 days; topical; daily; 90 days
Result: Increased serum ALT, AST, ALP, ACP, total bilirubin, direct bilirubin, indirect bilirubin, and liver MDA.
Decreased serum total protein, albumin, and liver SOD.
Increased liver weigh.
Induced 5.3-fold increase in hepatic CYP3A1 mRNA expression, 3.4-fold increase in PXR mRNA expression, 4.3-fold decrease in CYP2B1 mRNA expression, 2.7-fold decrease in CAR mRNA expression, and ~7-fold increase in hepatic CYP3A1 enzyme activity.
Animal Model: AB-strain (adult male, 4-6 months old, weight 450 mg, body length 38 mm)
Dosage: 50 ng/L; 7.5 mg/L
Administration: i.g.; daily; 7 days
Result: Increased fatness index significantly.
Reduced body length.
Caused looser heart structure, increased ventricular and arteriole volume, thinner heart walls, more vacuoles in the ventricular cavity, and increased numbers of hypertrophic cardiomyocytes with reduced cardiomyocyte density in both dose groups.
Identified 684 differentially expressed genes, with significant enrichment in cardiac energy metabolism pathways.
Increased heart tissue triglycerides; reduced ATP content in a concentration-dependent manner.
Slightly increased TG, reduced TC and low-density lipoprotein (LDL), and increased high-density lipoprotein (HDL).
Reduced mRNA expression of glycolysis genes GK and HK1, lipid transport gene abca1b, and UCP2.
Downregulated ion balance-related genes ryr2b, atp2a2a, and Pln in a concentration-dependent manner.
Upregulated myosin synthesis-related gene myl4, while downregulated myh7l, tpm4b, and tnnt2a.
Activated LEF1 gene expression abnormally in heart tissue compared to controls.
Increased cardiac ejection fraction significantly compared to controls.

化学信息

分子量 377.06
分子式 C13H12BrCl2N3O
CAS No. 116255-48-2
别名 糠菌唑

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础